GSK revises Relenza prescribing information to warn of abnormal behavior
GlaxoSmithKline updates Warnings and Precautions sections of zanamivir prescribing information
GSK revises Relenza prescribing information to warn of abnormal behaviorPostmarketing reports of delirium and abnormal behavior in patients with influenza who are receiving neuraminidase inhibitors have prompted GlaxoSmithKline to update the prescribing information for zanamivir (Tamiflu), another neuraminidase inhibitor, to include the same warnings.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.
